Tirzepatide is administered as a once-weekly subcutaneous injection. Half-life of approximately 5 days supports weekly dosing. Steady state is reached after 4 weeks.
Standard titration: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with each step held for at least 4 weeks. Pharmacokinetics: half-life ~5 days, steady state ~4 weeks, oral bioavailability nil (peptide). Subcutaneous administration: abdomen, thigh, upper arm — rotated weekly. Renal: no dose adjustment required for renal impairment.
This page references peer-reviewed publications listed on PubMed and FDA prescribing information labels. Methodology for source selection is documented on the Methodology page.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000